3 news items
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AUTL
2 Apr 24
cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AUTL
14 Mar 24
and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AUTL
12 Mar 24
views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those
- Prev
- 1
- Next